[ Axonics Modulation Technologies raises $20M in Series C ]
Axonics Modulation Technologies has raised $20 million in Series C funding.
Founded in 2012, Axonics Modulation Technologies is a privately-held venture backed company that has developed a novel implantable neuromodulation technology for patients with urinary and bowel dysfunction and can be further directed towards several clinical indications.
Proceeds from the financing will be used to conduct a pivotal clinical study in Overactive Bladder patients to gain U.S. FDA approval and prepare Axonics to access markets around the world.
|Founder / CEO||Raymond W. Cohen|
|Investors||Cormorant Asset Management|
|Previous Investors||Neomed Management|
|Advent Life Sciences|
|Edmond de Rothschild Investment Partners|
|Cormorant Asset Management|